Now the dispute lies in the hands of a federal judge after lawyers for both companies made final presentations on Wednesday at the close of a non-jury trial in New York federal court. J&J is seeking more than $7.2 billion in damages and interest from Boston Scientific as Guidant's successor, an amount that one analyst has characterized as a "major near-term risk" for a company with a market capitalization of about $19 billion as of Wednesday.